{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05378100",
            "orgStudyIdInfo": {
                "id": "IRB00322473"
            },
            "organization": {
                "fullName": "Johns Hopkins University",
                "class": "OTHER"
            },
            "briefTitle": "Ketamine for Multiple Sclerosis Fatigue",
            "officialTitle": "Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS)",
            "acronym": "INKLING-MS",
            "therapeuticArea": [
                "Other"
            ],
            "study": "ketamine-for-multiple-sclerosis-fatigue"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-12",
            "studyFirstSubmitQcDate": "2022-05-12",
            "studyFirstPostDateStruct": {
                "date": "2022-05-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Johns Hopkins University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "United States Department of Defense",
                    "class": "FED"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Sclerosis Fatigue"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 110,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ketamine-Ketamine",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this arm will receive two infusions of ketamine four weeks apart.",
                    "interventionNames": [
                        "Drug: Ketamine"
                    ]
                },
                {
                    "label": "Ketamine-Midazolam",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this arm will receive one infusion of ketamine followed four weeks later by an infusion of midazolam.",
                    "interventionNames": [
                        "Drug: Ketamine",
                        "Drug: Midazolam"
                    ]
                },
                {
                    "label": "Midazolam-Ketamine",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this arm will receive one infusion of midazolam followed four weeks later by an infusion of ketamine.",
                    "interventionNames": [
                        "Drug: Ketamine",
                        "Drug: Midazolam"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ketamine",
                    "description": "Infusion of ketamine 0.5 mg/kg over 40 minutes",
                    "armGroupLabels": [
                        "Ketamine-Ketamine",
                        "Ketamine-Midazolam",
                        "Midazolam-Ketamine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Midazolam",
                    "description": "Infusion of midazolam 0.05 mg/kg over 40 minutes",
                    "armGroupLabels": [
                        "Ketamine-Midazolam",
                        "Midazolam-Ketamine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Modified Fatigue Impact Scale (MFIS) Score",
                    "description": "The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.",
                    "timeFrame": "Baseline (infusion visit) through four weeks after the infusion."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Fatigue Severity Scale (FSS)",
                    "description": "The total score of the FSS ranges from 1 to 7. Higher scores denote more severe fatigue.",
                    "timeFrame": "Baseline (infusion visit) through four weeks after the infusion."
                },
                {
                    "measure": "Epworth Sleepiness Scale (ESS)",
                    "description": "The total score of the ESS ranges from 0 to 24. Higher scores denote more severe sleepiness.",
                    "timeFrame": "Baseline (infusion visit) through four weeks after the infusion."
                },
                {
                    "measure": "Beck Depression Inventory-II (BDI-II)",
                    "description": "The total score of the BDI-IIranges from 0 to 63. Higher scores denote more severe depression.",
                    "timeFrame": "Baseline (infusion visit) through four weeks after the infusion."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject must be a man or woman, 18 to 65 years of age, inclusive.\n* Subject must be medically stable based on physical examination, medical history, and vital signs\n* Subject must meet McDonald 2017 diagnostic criteria for multiple sclerosis based on the PI review of the medical records\n* Subject must complain from fatigue as one of their main symptoms and have a screening MFIS score equal or higher than the cutoff based on gender, age, and education displayed in Table-226\n* Subject must be ambulatory (able to walk at least 20 feet using bilateral assistance)\n* Subject must have internet and email access and ability to use a computer or tablet or smartphone\n* Subjects that are currently taking medication for alleviating fatigue (such as amantadine, modafinil and armodafinil, and amphetamine-like psychostimulants) at Screening are eligible to participate unless the medication is one of the disallowed therapies (Table 3). Subjects taking a fatigue medication at the Screening visit must have been receiving a stable dose for at least four weeks before the Screening visit and be willing to continue the medication at the same dose for the duration of the study.\n\nExclusion Criteria:\n\n* BDI-II score of more than 29 (indicating severe depression)\n* Having a known clear cause for secondary fatigue, such as untreated sleep apnea, untreated hypothyroidism, chronic liver disease, history of moderate to severe anemia (hemoglobin concentration of less than 9 gr/dl in men or less than 8 gr/dl in women).\n* Neurodegenerative disorders other than relapsing or progressive MS\n* Breastfeeding or pregnant\n* History of coronary artery disease or congestive heart failure\n* Uncontrolled hypertension at Screening (history of high blood pressure and screening systolic blood pressure \\>160 or diastolic blood pressure\\>100)\n* History of severe liver disease, including cirrhosis\n* Terminal medical conditions\n* Currently treated for active malignancy\n* Alcohol or substance abuse in the past year (except marijuana or other cannabinoids)\n* A history of intolerance or allergic or anaphylactic reaction to ketamine or midazolam\n* Clinically unstable medical or psychiatric disorders that require acute treatment as determined by the PI\n* History of severe or untreated coronary artery disease or history of congestive heart failure\n* History of prior ischemic or hemorrhagic stroke and cerebral vascular aneurysms.\n* History of recurrent seizures or epilepsy\n* Taking any disallowed therapy(ies), as noted in the protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lauren Vega, BSN",
                    "role": "CONTACT",
                    "phone": "410-614-1522",
                    "email": "ldimarc2@jhmi.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Johns Hopkins University",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mahsa Ghajarzadeh, MD, PhD",
                            "role": "CONTACT",
                            "email": "mghajar2@jhmi.edu"
                        },
                        {
                            "name": "Lauren Vega, BSN",
                            "role": "CONTACT",
                            "email": "Ldimarc2@jhmi.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "After completion of the study and publication of key findings, the study investigators will make Final Research Data available to researchers upon written request. Researchers must adhere to a data sharing agreement. This agreement requires users to:\n\n(1) use the data only for research purposes; (2) not share the data with unauthorized users; (3) ensure that the data are protected from unauthorized persons; (4) require that the data be returned or destroyed at the end of the analysis; (5) provide certification of IRB review and approval.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009103",
                    "term": "Multiple Sclerosis"
                },
                {
                    "id": "D000012598",
                    "term": "Sclerosis"
                },
                {
                    "id": "D000005221",
                    "term": "Fatigue"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000020278",
                    "term": "Demyelinating Autoimmune Diseases, CNS"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000003711",
                    "term": "Demyelinating Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12060",
                    "name": "Multiple Sclerosis",
                    "asFound": "Multiple Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "asFound": "Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8364",
                    "name": "Fatigue",
                    "asFound": "Fatigue",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22098",
                    "name": "Demyelinating Autoimmune Diseases, CNS",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M6909",
                    "name": "Demyelinating Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008874",
                    "term": "Midazolam"
                },
                {
                    "id": "D000007649",
                    "term": "Ketamine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000778",
                    "term": "Anesthetics, Dissociative"
                },
                {
                    "id": "D000018686",
                    "term": "Anesthetics, Intravenous"
                },
                {
                    "id": "D000018681",
                    "term": "Anesthetics, General"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000018691",
                    "term": "Excitatory Amino Acid Antagonists"
                },
                {
                    "id": "D000018683",
                    "term": "Excitatory Amino Acid Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000759",
                    "term": "Adjuvants, Anesthesia"
                },
                {
                    "id": "D000006993",
                    "term": "Hypnotics and Sedatives"
                },
                {
                    "id": "D000014151",
                    "term": "Anti-Anxiety Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018757",
                    "term": "GABA Modulators"
                },
                {
                    "id": "D000018682",
                    "term": "GABA Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10674",
                    "name": "Ketamine",
                    "asFound": "Nerve",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11845",
                    "name": "Midazolam",
                    "asFound": "Course",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4108",
                    "name": "Anesthetics, Dissociative",
                    "relevance": "LOW"
                },
                {
                    "id": "M20766",
                    "name": "Anesthetics, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M20761",
                    "name": "Anesthetics, General",
                    "relevance": "LOW"
                },
                {
                    "id": "M20771",
                    "name": "Excitatory Amino Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4089",
                    "name": "Adjuvants, Anesthesia",
                    "relevance": "LOW"
                },
                {
                    "id": "M10043",
                    "name": "Hypnotics and Sedatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M16905",
                    "name": "Anti-Anxiety Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M20827",
                    "name": "GABA Modulators",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AdjAn",
                    "name": "Adjuvants, Anesthesia"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                }
            ]
        }
    },
    "hasResults": false
}